Bixia Tang

3.0k total citations
123 papers, 1.2k citations indexed

About

Bixia Tang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bixia Tang has authored 123 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Oncology, 50 papers in Molecular Biology and 27 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bixia Tang's work include Cancer Immunotherapy and Biomarkers (45 papers), Cutaneous Melanoma Detection and Management (41 papers) and CAR-T cell therapy research (35 papers). Bixia Tang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (45 papers), Cutaneous Melanoma Detection and Management (41 papers) and CAR-T cell therapy research (35 papers). Bixia Tang collaborates with scholars based in China, Ethiopia and United States. Bixia Tang's co-authors include Chuanliang Cui, Lu Si, Xinan Sheng, Zhihong Chi, Jun Guo, Bin Lian, Xieqiao Yan, Lili Mao, Siming Li and Yan Kong and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Bixia Tang

112 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bixia Tang China 20 908 458 338 197 186 123 1.2k
Xieqiao Yan China 20 882 1.0× 422 0.9× 248 0.7× 324 1.6× 229 1.2× 112 1.2k
Frank M. Speetjens Netherlands 20 617 0.7× 326 0.7× 613 1.8× 63 0.3× 137 0.7× 50 1.1k
Rodrigo Ramella Munhoz Brazil 14 822 0.9× 309 0.7× 395 1.2× 87 0.4× 281 1.5× 56 1.2k
Chang Gon Kim South Korea 11 470 0.5× 282 0.6× 364 1.1× 90 0.5× 130 0.7× 15 893
Boel Ragnarsson-Olding Sweden 20 1.1k 1.2× 405 0.9× 326 1.0× 240 1.2× 107 0.6× 30 1.4k
Toby Mellows United Kingdom 12 885 1.0× 357 0.8× 643 1.9× 186 0.9× 244 1.3× 17 1.5k
Raid Aljumaily United States 15 1.0k 1.1× 285 0.6× 272 0.8× 406 2.1× 253 1.4× 81 1.3k
Christian Idel Germany 16 466 0.5× 265 0.6× 293 0.9× 68 0.3× 123 0.7× 47 867
James G. Jakowatz United States 16 602 0.7× 342 0.7× 268 0.8× 169 0.9× 124 0.7× 44 948
María Ochoa de Olza Spain 14 521 0.6× 159 0.3× 275 0.8× 36 0.2× 152 0.8× 30 724

Countries citing papers authored by Bixia Tang

Since Specialization
Citations

This map shows the geographic impact of Bixia Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bixia Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bixia Tang more than expected).

Fields of papers citing papers by Bixia Tang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bixia Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bixia Tang. The network helps show where Bixia Tang may publish in the future.

Co-authorship network of co-authors of Bixia Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Bixia Tang. A scholar is included among the top collaborators of Bixia Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bixia Tang. Bixia Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Siming, J. B. Wei, Huayan Xu, et al.. (2025). A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy. World Journal of Urology. 43(1). 206–206.
2.
Tang, Bixia, et al.. (2025). Experimental investigation on the post-fire behavior of CMT-WAAM 2209 duplex stainless steel. Journal of Constructional Steel Research. 235. 109835–109835. 1 indexed citations
3.
Tang, Bixia, Xinan Sheng, Shusuan Jiang, et al.. (2025). Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.. Journal of Clinical Oncology. 43(5_suppl). 657–657. 2 indexed citations
4.
Tang, Bixia, Mei Liu, Yingjie Xu, et al.. (2025). Mechanical properties, microstructure, and theoretical modeling of CMT-WAAM 2209 duplex stainless steel. Journal of Constructional Steel Research. 235. 109892–109892. 1 indexed citations
5.
6.
Mao, Lili, Jie Dai, Xue Bai, et al.. (2024). Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study.. Journal of Clinical Oncology. 42(16_suppl). e21527–e21527. 1 indexed citations
7.
Tang, Bixia, Rong Duan, Xieqiao Yan, et al.. (2024). Natural history of bone-only metastasis in renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 42(4). 119.e17–119.e22. 1 indexed citations
8.
Tang, Bixia, Rong Duan, Xiaoshi Zhang, et al.. (2024). Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma. The Oncologist. 29(6). e822–e827. 4 indexed citations
9.
10.
Dai, Jie, Xiaoting Wei, Xue Bai, et al.. (2024). Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study. Dermatology Practical & Conceptual. 14(1). e2024026–e2024026. 1 indexed citations
11.
Mao, Lili, Jie Dai, Xue Bai, et al.. (2024). Neoadjuvant pembrolizumab and lenvatinib in resectable mucosal melanoma: NeoPlus study update.. Journal of Clinical Oncology. 42(16_suppl). 9580–9580. 2 indexed citations
12.
Cui, Chuanliang, Xuan Wang, Bin Lian, et al.. (2022). OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study. Journal for ImmunoTherapy of Cancer. 10(4). e004307–e004307. 38 indexed citations
13.
Li, Siming, Xiaowen Wu, Xieqiao Yan, et al.. (2022). Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. Journal for ImmunoTherapy of Cancer. 10(2). e004036–e004036. 33 indexed citations
14.
15.
Wang, Yang, Bin Lian, Lu Si, et al.. (2022). Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I–III. European Journal of Cancer. 175. 196–203. 3 indexed citations
16.
Bai, Xue, Michelle Kim, Gyulnara G. Kasumova, et al.. (2021). Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. Journal for ImmunoTherapy of Cancer. 9(2). e002092–e002092. 8 indexed citations
17.
Yan, Xieqiao, Xinan Sheng, Zhihong Chi, et al.. (2021). Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. Journal of Clinical Oncology. 39(8). 881–889. 36 indexed citations
18.
Sheng, Xinan, Dengfeng Cao, Jianlin Yuan, et al.. (2018). Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. European Journal of Cancer. 100. 1–7. 37 indexed citations
19.
Bai, Xue, Yan Kong, Zhihong Chi, et al.. (2017). MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clinical Cancer Research. 23(20). 6120–6127. 72 indexed citations
20.
Lian, Bin, Lu Si, Chuanliang Cui, et al.. (2013). Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma. Clinical Cancer Research. 19(16). 4488–4498. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xieqiao Yan Breakdown of academic impact, for papers by Frank M. Speetjens Breakdown of academic impact, for papers by Rodrigo Ramella Munhoz Breakdown of academic impact, for papers by Chang Gon Kim Breakdown of academic impact, for papers by Boel Ragnarsson-Olding Breakdown of academic impact, for papers by Toby Mellows Breakdown of academic impact, for papers by Raid Aljumaily Breakdown of academic impact, for papers by Christian Idel Breakdown of academic impact, for papers by James G. Jakowatz Breakdown of academic impact, for papers by María Ochoa de Olza
Rankless by CCL
2026